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How Are We Going to Live With Alzheimer's Disease? 
Abstract 
Alzheimer’s disease confronts us with an ethical challenge: How do we live with dignity and quality of life 
in the face of progressive disability and, ultimately, death? Patients’ cognitive and decision-making 
impairments often make them unable to answer this question, and when professionals who provide 
services for older adults fail to recognize and accommodate these impairments, patients suffer. Patients 
and their caregivers need a health care system that fosters caregiving so that each will live with dignity 
and well-being. Another way to answer this question is to discover treatments that prevent disabling 
cognitive impairments, but this strategy will require expanding the Alzheimer’s label to include people who 
do not have dementia or who are even cognitively normal. Controversies are likely to occur over how best 
to describe the Alzheimer’s problem, measure the value of early diagnosis and treatment, and live with a 
brain at risk. 
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How Are We Going To Live With Alzheimer’s Disease? 
Abstract 
Alzheimer’s disease confronts us with an ethical challenge: 
How do we live with dignity and quality of life in the face of 
progressive disability and, ultimately, death? Patients’ 
cognitive and decision-making impairments often make them unable 
to answer this question, and when professionals who provide 
services for older adults fail to recognize and accommodate 
these impairments, patients suffer. Patients and their 
caregivers need a health care system that fosters caregiving so 
that each will live with dignity and well-being. Another way to 
answer this question is to discover treatments that prevent 
disabling cognitive impairments, but this strategy will require 
expanding the Alzheimer’s label to include people who do not 
have dementia, or who are even cognitively normal. Controversies 
are likely to occur over how best to describe the Alzheimer’s 
problem, measure the value of early diagnosis and treatment, and 
live with a brain at risk.  
 
Rising prevalence, increasing costs, and persistent failure 
to discover effective pharmacologic treatments have made 
Alzheimer’s disease a national problem that evokes disaster 
images such as “silver tsunami” and “epidemic.” The United 
States is responding. In 2011 President Obama signed the 
National Alzheimer’s Project Act into law. Commonly called NAPA, 
it has led to an integrated national plan.(1)   
As policy makers develop and implement this plan, they 
should recognize that Alzheimer’s disease confronts patients 
with an ethical challenge--“How do I live with dignity and 
quality of life in the face of progressive disability and, 
ultimately, death?” A system of laws, ethics, and social norms 
grants each of us the freedom to answer this question and to 
respect each other’s autonomy to do the same, but patients with 
Alzheimer’s disease face challenges in their ability to 
participate in this system.  
Over time, patients not only develop disabilities 
performing daily tasks, such as taking their medications safely, 
but also develop impairments in deciding how best to manage 
these problems, a phenomena that reflects how patients often 
underestimate or even do not recognize their disabilities.(2) 
They also develop impairments in their decision-making 
abilities.(2-4) The failure to recognize and accommodate these 
complex disabilities can cause a patient to suffer harms; such 
as losses of dignity and respect, abuse, neglect, and 
exploitation. Our national plan for Alzheimer’s disease 
therefore requires an ethical response. 
First, early in the disease, patients vary in whether they 
retain the ability to make day-to-day decisions about matters 
such as money management and living arrangements. Professionals 
who provide services for older adults, especially in long-term 
care, and the legal, banking, and financial services industries 
need methods to assess and monitor their clients’ decision-
making abilities, and, when they detect impairments, take 
appropriate action. Secondly, as cognitive and functional 
impairments worsen, patients need other people, typically a 
family member or friend, to care for them. As these caregivers 
witness the person “die twice,” first in mind and then a few 
years later in body, they make day-to-day and often ethically 
charged decisions for the patient as they themselves experience 
notable morbidity, especially depression.(5) Patients and their 
caregivers need a health care system that fosters caregiving so 
that each will live with dignity and well-being. 
Another response to prevent the harms of losses of dignity 
and respect, as well as abuse, neglect, and exploitation, is to 
prevent Alzheimer’s disease, and one of goals of the US national 
Alzheimer’s plan (released in 2012) is that by 2025, the United 
States will discover a treatment that prevents, halts, or even 
reverses the onset of disabling cognitive impairments. 
Partnerships between the NIH, academia, and the pharmaceutical 
industry have launched large-scale studies to reach this 
ambitious goal.(6,7) Discovering an effective treatment requires 
a diagnosis prior to dementia or even mild cognitive 
impairments, an approach that will need to accommodate a new 
understanding of the label “Alzheimer’s disease:” It does not 
necessarily equate to having dementia or even any symptoms of 
cognitive impairment.  
This understanding will present new ethical and policy 
challenges. As the number of people with Alzheimer’s disease 
expands along a diverse continuum that includes people at risk 
of disability to those who are extremely disabled, controversies 
are likely to occur over how best to describe the Alzheimer’s 
disease problem, how big it is, how to demonstrate the value of 
early diagnosis and treatment, and how to live with a brain at 
risk. 
Facilitating Decision-Making 
Medicine, psychology, and the law have made substantial 
progress developing and translating a conceptual model of 
decision-making capacity. The model requires that for a given 
decision, the clinician assess the person’s decision-making 
abilities. This assessment informs the clinician’s judgment 
whether the person is able to provide informed consent, or 
instead, needs assistance, or even someone else, to provide 
consent.(8,9) Studies show that patients with very mild to 
moderate stage Alzheimer’s disease have substantial variability 
in their decision-making abilities. They are able to express a 
choice, meaning they can state what they do or do not want, such 
as declining to attend an adult day-care program, but they often 
have clinically significant impairments in their abilities to 
understand relevant facts and appreciate how an intervention 
such as adult care will help them.(4,10) Comparing patients’ 
capacity to make different decisions shows that they may retain 
the capacity to make one kind of decision, such as appointing a 
surrogate, but lack the capacity to make a more complex 
decision, such as whether to join a research study that involves 
a neurosurgical intervention.(11)  
These findings explain why most very mild to moderate stage 
patients either make a decision with someone else or someone 
else makes decisions for them,(12) and that neither the 
diagnostic label of Alzheimer’s disease dementia nor the scores 
on cognitive and functional measures from very mild to moderate 
stage disease can substitute for an assessment of decision-
making capacity.  
Medical decisions are, of course, just one kind of 
important and often ethically charged decision patients make. 
They also make decisions about long-term care, and legal, 
banking, and other financial matters. Although the professionals 
in these fields may not know whether their clients have 
Alzheimer’s disease, cognitive changes that impact everyday 
decision-making are common among older adults.(13) It would be 
very beneficial if these professionals had the skills to assess 
older adults’ decisional abilities. The more they possess these 
skills, the better they can decide whether an older adult’s 
decision is a decision to be respected, or instead, signals a 
problem in need of monitoring or even intervention.  
These skills are especially important for professionals 
working in the financial services and banking industries. They 
are essentially on the front lines of screening for cognitive 
impairment because declines in financial decision-making 
capacity are among the earliest functional changes seen in 
people with Alzheimer’s disease.(14) These professionals need 
professional standards and regulatory guidance that set out 
their obligations to identify people with impaired financial 
decision-making capacity, training in how to do this, and, how 
to address people with impaired capacity.(15,16) 
However, it might be argued that non-medical professionals 
should not assess older adults’ decision-making abilities 
because such assessments are medical matters. Certainly, in high 
stakes or contested decisions such as a major asset transfer or 
whether to move from one home to another, medical consultation 
may well be essential, but as a matter of daily practice, 
physicians and the courts cannot be brought into adjudicating 
whether a patient has capacity to make each and every daily 
decision. 
Older adults should at least expect that professionals who 
work with them are skilled in effectively communicating with 
them and their caregivers. The ability to assess capacity is 
among the skills of a good teacher. When, for example, an adult 
protective services caseworker asks an older adult who has had 
several emergency department visits for medication errors, “Do 
you think that using a weekly pill box for your medications 
could benefit you?” the caseworker is assessing the client’s 
ability to appreciate the benefits of an intervention, which is 
one of the decision-making abilities physicians use to judge 
capacity. The caseworker is also engaging in good communication 
with someone whose problem managing medications suggests the 
presence of a cognitive impairment.(4) Caseworkers and discharge 
planners may find an instrument such as the Assessment of 
Capacity for Everyday Decisionmaking useful to assess and 
document a person’s decision-making abilities.(3,4)  
Enduring The Unendurable 
This section’s title is taken from one of Arthur Kleinman’s 
essays about his wife’s decline and ultimate death from 
Alzheimer’s disease.(17,18) Kleinman, a psychiatrist and 
anthropologist, has studied the ways patients make sense of 
disease and the role clinicians have in eliciting patients’ 
illness experiences.(19) Turning these skills to understanding 
his experiences caring for his spouse, he arrived at insights of 
substantial ethical and policy importance.  
Kleinman came to see how the person with the disease and 
the person who cares for them essentially exchange roles. “She 
is happy much of the time. It is me, the caregiver, who, more 
often, is sad and despairing.”(17) Studies reinforce this. 
Patients consistently rate their quality of life and functional 
abilities better than caregivers rate patients’ quality of life 
and functional abilities,(2,20) and caregivers experience 
notable symptoms of depression.(5) In short, not only patients 
but their caregivers have an illness experience.  
Kleinman’s solution to endure this gradual exchange of 
roles is caregiving, a deeply interpersonal practice that 
resonates with matters of living, self, and dignity.(17) Because 
caregiving is an indelible part of what it means to be human, it 
is therefore among the foundations of our common moral 
experience. People such as Kleinman use this experience to make 
day-to-day and often ethically charged decisions. Unfortunately, 
medicine and the health care system have largely neglected this 
foundation; for example, caregivers do not have ready access to 
education and training. In the care of people with Alzheimer’s 
disease, this is a notable shortcoming because patients often 
underestimate or even entirely deny that they have functional 
problems, and, as a result, may decline care. In such a 
situation, the caregiver is the ethically appropriate means to 
provide patient-centered care. What follows are initiatives that 
policy makers can take to foster caregiving. 
A 2012 NAPA-commissioned review of interventions to support 
caregivers found multiple randomized and controlled trials and 
translational studies that show psychosocial and environmental 
interventions and training can foster caregiving that, in turn, 
benefits both patients and their caregivers.(21) The Resources 
for Enhancing Alzheimer’s Caregiver Health (REACH) studies, for 
example, show that intervention strategies such as education, 
problem solving, and telephone support groups can improve 
caregiver mood and well-being and reduce patient morbidity.(22) 
Unfortunately, interventions such as REACH are not part of the 
routine care of a person with Alzheimer’s disease in the same 
manner as prescriptions for mildly effective symptomatic 
medications. A prescription for caregiver training should be as 
available as, for example, nutritional consultation and 
education are part of the routine care of a patient with 
diabetes.  
Other interventions that can foster caregiving include 
redesigning the electronic medical record (EMR).(23) The default 
design records the care of an individual patient who, via a 
“patient portal,” remotely accesses it to check results and to 
communicate with providers. For patients who need caregivers, 
this design is insufficient. Caregivers need access to this 
exchange of patient information.. Medicare requirements for how 
clinicians should use the EMR need to include a record of the 
patient’s caregivers and their roles, and allow them access to 
the patient’s portal.  
As patients decline, they have increasing needs for both 
palliative and hospice care, but delivering hospice care to them 
faces structural problems. Predicting that a patient with 
dementia has a six-months or less life expectancy and is 
therefore eligible for the Medicare hospice benefit is 
challenging.(24) Patients often live beyond this life 
expectancy, putting them at great risk of being discharged from 
hospice care. A sensible reform would be to allow patients with 
severe stage dementia to enroll and remain in hospice as long as 
it fits their goals of care, rather than their life expectancy. 
“Enduring the unendurable” has been about the ethics of 
living with progressive and disabling cognitive impairments; 
that is, living with dementia. For much of the 20th century, 
Alzheimer’s disease and dementia were tightly linked 
concepts.(25) Now, at the beginning of the 21st century, that 
link is beginning to fracture. In its place is a new concept of 
Alzheimer’s disease, that it is a continuum of decline beginning 
when a person is cognitively normal. This presents novel 
challenges to living with Alzheimer’s disease.   
Preparing For The ‘Brain At Risk’ 
Our approaches to Alzheimer’s disease diagnostics and 
treatment as well as our understandings of its prevalence, 
costs, and personal and family burdens have relied on diagnostic 
criteria issued in 1984.(26) Often called the “McKhann 
criteria,” shorthand for their lead author Guy McKhann, the 
criteria define Alzheimer’s disease as a clinical diagnosis 
explained by a characteristic pathology. The clinical diagnosis 
describes a person whose history of cognitive and functional 
impairments follows a stereotypical pattern. The pathology that 
explains this dementia is commonly called “plaque and tangle 
Alzheimer’s disease,” because between the neurons are dense 
deposits of a protein called amyloid (amyloid plaques) and 
within the deceased neurons, there are tangles of fibrils (tau 
tangles).  
By the close of the 20th century, researchers argued that 
numerous inconsistencies between what the 1984 criteria 
suggested researchers should observe versus what they actually 
did observe required new criteria. Their most provocative 
observations came from studies performing serial measures of 
older adults’ cognition, function, brain structure and function, 
and tissues such as spinal fluid; and post-mortem brain 
autopsy.(27) First, Alzheimer’s plaque and tangle pathology can 
be found post-mortem in older adults who were cognitively 
normal. Second, older adults with dementia typically have not 
only Alzheimer’s pathology, but other pathologies as well, most 
notably vascular disease. Third, distinct measures of brain 
pathophysiology, commonly called “biomarkers,” seem to predict 
which older adults start out cognitively normal, but, over time, 
develop disabling cognitive impairments.  
In 2011, three National Institute on Aging-Alzheimer’s 
Association workgroups revised the criteria for dementia caused 
by Alzheimer’s disease and added two non-dementia stages to the 
disease: a mild cognitive impairment stage characterized by 
measurable impairments in cognition without dementia and a stage 
defined entirely by biomarkers and their connection to future 
cognitive impairment, called “preclinical Alzheimer’s 
disease.”(28-30) The International Working Group for New 
Research Criteria for the Diagnosis of Alzheimer’s Disease has 
also proposed similar criteria for “asymptomatic at risk for 
Alzheimer’s disease.”(31) Their lingua franca are the biomarkers 
and genes that might identify who will progress from cognitive 
normality or mild cognitive impairment to Alzheimer’s disease 
dementia. 
“Preclinical” or “asymptomatic at risk for Alzheimer’s 
disease” are not concepts ready for clinical practice, but they 
are eligibility criteria for ongoing studies whose results will 
standardize biomarkers, distinguish normal from abnormal 
biomarker levels, and identify people in need of treatment. 
McKhann, some twenty-seven years after the publication of the 
criteria that informally bear his name, explains a view echoed 
by his fellow NIA workgroup members, that the most important of 
these studies are clinical trials. “The ultimate goal of these 
recommendations is to realign the clinical and research 
diagnostic approach with potential therapies…. Waiting for the 
appearance of dementia would be tantamount to physicians trying 
to prevent heart disease in only those who have had a myocardial 
infarction.”(32)  
The National Institutes of Health (NIH), in cooperation 
with pharmaceutical industry partners, has committed at least 
$100 million to four clinical trials whose goal is to identify 
cognitively normal people with either a genetic or biomarker-
defined risk of cognitive decline in order to intervene with a 
pharmacological intervention that will slow this decline. The 
Anti-Amyloid in Asymptomatic Alzheimer’s Study (the A4 Study), 
for example, a joint NIH- and Eli Lilly–sponsored randomized and 
controlled trial, is enrolling cognitively normal adults ages 
65–85 who have elevated amyloid as detected on a PET scan to 
test whether three-and-a-half years of treatment with an anti-
amyloid drug slows the rate of cognitive decline.(7) Similar 
studies are ongoing or are soon to start in cognitively normal 
people who are at heightened genetic risk of developing 
Alzheimer’s disease dementia. If the studies are successful, 
they will begin to redefine Alzheimer’s disease into a 
biomarker-based diagnosis that is largely independent of the 
clinical expression of the disease. 
The conceptual model of these studies comes from clinical 
trials for other diseases of aging whose results established 
tight links among a biomarker, a drug that targets the 
biomarker, and an outcome measuring the chance of a future 
clinical event.(33) Clinical trials have transformed diseases 
such as heart disease and osteoporosis from clinical to 
biomarker-based diagnoses, as, for example, the biomarker of 
cholesterol engenders statin treatment to reduce the risk of 
heart attack. Diagnosing and treating Alzheimer’s disease in a 
preclinical stage has tremendous appeal to both an individual’s 
health and the public health, but this also presents ethical and 
policy challenges. 
A common feature of chronic diseases of aging is that they 
unfold slowly and insidiously, and then, in a thunderclap, the 
patient is sick. Stroke, heart attack, hip fracture, and acute 
congestive heart failure are dramatic events that share common 
features. They are easily measured and therefore easily 
quantified. These events are also readily understood by 
researchers, clinicians, patients, and policy makers. These 
features are of substantial advantage to translating into 
clinical practice the results of trials in diabetes, 
cardiovascular disease, and osteoporosis.  
Alzheimer’s disease prevention trials do not measure these 
kinds of events. Their primary endpoint is the slope of decline 
in a measure of cognition. This measure is a composite of 
several cognitive tests, most of which are not used in clinical 
practice. This endpoint presents a pressing problem: how to 
translate it into clinical practice and treatment guidelines? 
This problem will have substantial importance and urgency 
because the number of people who are “biomarker positive” and 
therefore potentially eligible for a prevention therapy could be 
in the millions. For example, among adults age sixty-five and 
older who are cognitively normal, about one-third are amyloid 
positive on PET scans.(28)  
Addressing this problem will require approaches that use 
the results of clinical trials and longitudinal cohort studies 
to create prediction models, also called algorithms, that 
demonstrate the kinds of patients who will benefit from 
interventions.(34) What data will be used, and how the models 
will be designed, interpreted, and updated are matters of 
interrelated scientific, ethical, and public policy importance. 
Unlike the Food and Drug Administration–regulated drug approval 
process, treatment algorithms and guidelines are typically 
developed by professional societies. They are more likely to 
experience the conflicts of interest that arise when 
professional, private, and scientific interests compete.(35) 
As one or more combinations of biomarkers defines the 
disease, the prevalence of people with Alzheimer’s disease will 
increase, but as it increases, it will begin to encompass a 
diverse spectrum of patients, ranging from those who have 
dementia, to persons who are cognitively normal but “biomarker 
positive.” These different kinds of people with the disease will 
undermine the ability of having one prevalence number to express 
the magnitude of the problem and therefore its costs.  
As people are labeled with biomarker-defined Alzheimer’s 
disease, they will have to live with and make sense of a label 
that renegotiates the boundaries between a healthy brain versus 
a brain at risk for a disease Americans fear even more than 
cancer.(36,37) People in the preclinical stage of the disease 
may well be working and want to purchase long-term care 
insurance, so legal reforms and professional initiatives will be 
needed to minimize discrimination in employment and 
insurability. Over time, despite treatment, some patients may 
develop symptoms and signs of cognitive impairment. This 
reiterates the importance of training professionals in law, 
banking, and finance on how to assess decision-making abilities 
and, if they detect impairments, the actions they should take. 
Conclusion 
One afternoon at the Memory Center where I care for 
patients, a caregiver interrupted his narrative of his wife’s 
decline and insisted, “I have Alzheimer’s disease!” In a sense, 
he’s right. As researchers unleash Alzheimer’s disease from the 
category of people with dementia to a continuum of cognitive 
decline, each of us is even more likely to have it. Short of a 
cure, prevention will delay but not eliminate cognitive 
impairment. As this impairment slowly degrades a patient’s 
autonomy, the disease will inevitably engage others and these 
caregivers will suffer as well. Whether as patients or as 
caregivers, we all have Alzheimer’s disease. The question we 
must engage is how should we live with it? 
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